Antihypertensive efficacy and safety of azilsartan medoxomil in patients with CАD, obesity and metabolic disorders. According to the CONSTANT study

Background: epidemiological studies show that the most common arterial hypertension (AH) is complicated by coronary artery disease (CAD), such patients are classified as very high risk. Effective BP control in this category of patients is critical. Therefore, assessing the efficacy and safety of current antihypertensive drugs in patients with AH and CAD against obesity or overweight is an important task. Purpose. Evaluation of antihypertensive efficacy and safety of azilsartan medoxomil in patients with overweight or obesity and stable CAD. Materials and methods. 335 patients with stable CAD and overweight or obese enrolled in the international multicenter observational non-interventional prospective study CONSTANT with azilsartan medoxomil according to the approved label. The observation period is 6 months. Results. The dynamics of SBP by visit 4 (6 months) was 30,1±15,3 mmHg, DBP – 12,5±10,4 mmHg (r≤0,001). Overall, 84,5% of patients enrolled in the study achieved BP targets across the group. Response to therapy (reduction in SBP by at least 20 mm Hg, DBP of 10 mm Hg) was obtained in 75,2% of patients. In patients who did not take statins, the level of cholesterol, triglycerides and LDL decreased significantly (p<0,001), the HDL did not change significantly. In patients with diabetes mellitus, a decrease in glycated hemoglobin was recorded (p<0,001). Overall, a decrease in waist circumference was observed across the group (p<0,005). Conclusion. Azilsartan medoxomil has high antihypertensive properties, the ability to influence the metabolic profile and volume of adipose tissue, as well as tolerability comparable to placebo, which makes it the drug of choice in patients with AH with CAD and obesity or overweight in real clinical practice.